Integrating Multi-Omics Mendelian Randomization and Functional Validation to Identify Novel Apoptosis Regulators in

Bin Zhu1, Suli Wang1, Wenli Zhao1

  • 1Department of Hematology, The Sixth People's Hospital Affiliated to Shanghai Jiaotong University South Branch, Shanghai Fengxian District Central Hospital, Shanghai, China.

Insights

This study identifies IER3IP1 as a novel oncogene in follicular lymphoma (FL), promoting cancer growth and resistance to Rituximab therapy. Targeting IER3IP1 may restore apoptosis and improve treatment outcomes for FL patients.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Dysregulation of apoptosis is a key feature of follicular lymphoma (FL).
  • The genetic drivers influencing apoptosis in FL are not fully understood.
  • Identifying these drivers is crucial for developing targeted therapies.

Purpose of the Study:

  • To identify and functionally validate apoptosis-related genes causally linked to FL.
  • To investigate the role of identified genes in FL pathogenesis and treatment response.
  • To explore potential therapeutic targets for follicular lymphoma.

Main Methods:

  • Multi-omics Mendelian randomization (MR) study integrating FL GWAS with mQTL, eQTL, and pQTL data.
  • Summary data-based MR (SMR) and colocalization analyses for candidate gene identification.
  • Validation in external transcriptomic cohorts, FL patient tissues (RT-qPCR), and in vitro functional assays.

Main Results:

  • MR analysis identified IER3IP1, PRKCZ, and CD40 as potentially causal genes in FL.
  • IER3IP1 mRNA levels were elevated in FL tissues and it functions as an oncogene promoting FL cell proliferation and migration.
  • IER3IP1 depletion enhanced FL cell sensitivity to Rituximab by upregulating CD20 via the XBP1/FOXO1 axis.

Conclusions:

  • IER3IP1 is a novel causal oncogene in follicular lymphoma pathogenesis.
  • The IER3IP1-mediated XBP1/FOXO1/CD20 axis contributes to targeted therapy resistance.
  • IER3IP1 represents a promising therapeutic target to enhance Rituximab efficacy in FL.